Bastiaannet Esther, Pilleron Sophie
Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, CH-8001, Zurich, Switzerland.
Ageing, Cancer, and Disparities Research Unit, Department of Precision Health, Luxembourg Institute of Health, 1A-B, Rue Thomas Edison, 1445, Strassen, Luxembourg.
Curr Oncol Rep. 2025 Mar;27(3):290-311. doi: 10.1007/s11912-025-01638-6. Epub 2025 Feb 15.
We examined the latest epidemiological research on age-related differences in cancer treatment and selected outcomes, among patients with cancer aged 60 and above in comparison to younger patients.
Colorectal, pancreatic and lung cancers were studied most often. Most studies were conducted in Europe or the United States of America (USA) within single centers. For unselected patients, older patients receive less treatment, and their survival, regardless of the metric used (cancer-specific survival or overall survival), was poorer than that of middle-aged patients. Age-related differences in treatment and outcomes were more pronounced in patients aged over 80 years. However, among patients selected for treatment, complications, adverse events rates and survival probabilities were comparable between older and younger patients. Treatment differences, especially the omission of therapy, were often smaller for good prognosis cancer types. The likelihood of receiving treatment decreased as age increases, regardless of the cancer types, treatment, countries and setting. More research on treatment in older patients with cancer, especially the frailest and the oldest, is urgently needed as there is still a lack of data to tailor treatment.
我们研究了癌症治疗中年龄相关差异以及特定结局的最新流行病学研究，比较了60岁及以上癌症患者与年轻患者的情况。
结直肠癌、胰腺癌和肺癌是研究最多的癌症类型。大多数研究在欧洲或美国的单一中心进行。对于未经过筛选的患者，老年患者接受的治疗较少，无论使用何种指标（癌症特异性生存或总生存），其生存率都低于中年患者。80岁以上患者在治疗和结局方面的年龄相关差异更为明显。然而，在选择接受治疗的患者中，老年患者和年轻患者的并发症、不良事件发生率和生存概率相当。对于预后良好的癌症类型，治疗差异，尤其是治疗的省略，通常较小。无论癌症类型、治疗方式、国家和环境如何，接受治疗的可能性都随着年龄的增加而降低。由于仍然缺乏为老年癌症患者量身定制治疗的数据，因此迫切需要对老年癌症患者，尤其是最虚弱和最年长的患者进行更多的治疗研究。
Zotero 插件